| Invasight–Wille Finance: investment, 202206 seed financing round totalling CHF4.5m incl co-investor Wille Finance AG |
2022-06-07 |
| Invasight–Zürcher Kantonalbank: investment, 202206 seed financing round totalling CHF4.5m incl co-investor ZKB |
2022-06-07 |
| BMS–Immatics: cancer immunotherapy, 202201– collab strategic alliance expansion $60m upfront + $700 milestones per programme using ACTallo platform |
2022-06-02 |
| Merck (DE)–Proxygen: molecular glue degraders, 202206– strategic multi-year collab + license agreem up to €495m plus royalties |
2022-06-02 |
| Upstream Bio–HBM: investment, 202206 financing round Series A totalling $200m incl co-investor HBM Healthcare Investments |
2022-06-02 |
| Upstream Bio–SEVERAL: investment, 202206 financing round Series A $200m co-led by OrbiMed + Maruho Co Ltd |
2022-06-02 |
| Agilent–Mettler-Toledo: lab automation, –202206 collab developm + product integration automated + digitalised sample prep for LC/GC workflow |
2022-06-01 |
| Firmenich–DSM: investment, 202205– merger with former DMS owners holding 65.5% + Firmenich owners receiving 34.5% plus €3.5b in cash ANNOUNCED |
2022-05-31 |
| Minoryx–SEVERAL: credit, 202205 complementary bank debt to Series C financing round (both tog totalling €51m) |
2022-05-31 |
| Minoryx–SEVERAL: investment, 202205 financing round Series C (incl complementary bank totalling €51m) led by Columbus VP + Caixa Capital Risc |
2022-05-31 |
| Rigenerand–Evotec: investment, 202205–202207 acquisition 100% for €23m |
2022-05-30 |
| Rigenerand–Xyence Capital: investment, 202205 existent Xyence is majority shareholder at time of sale of Rigenerand to Evotec |
2022-05-30 |
| Irubis–EU (govt): grant, 202005– grant €1.3m from EIC Accelerator Pilot Programme |
2022-05-26 |
| Aalto Bio Reagents–Biosynth Carbosynth: investment, 202205 acquisition of Aalto by Biosynth Carbosynth |
2022-05-25 |
| CureVac–myNEO: drug target discovery, 202205– collab research + option agreem antigen targets for mRNA cancer vaccines |
2022-05-25 |
| Alithea Genomics–Novalis Biotech: investment, 202205 seed financing round totalling CHF1m incl lead investor Novalis Biotech Acceleration Fund |
2022-05-24 |
| Alithea Genomics–OTHER: investment, 202205 seed financing round totalling CHF1m incl Swiss-based private investors as co-investors |
2022-05-24 |
| Alithea Genomics–SEVERAL: investment, 202205 seed financing round CHF1m led by Novalis Biotech Acceleration Fund |
2022-05-24 |
| Almirall–Evotec: drug discovery services, 202205– collab multi-target RnD alliance in medical dermatology |
2022-05-19 |
| Apollo Global Management–Sofinnova: life science financing, 202205– strategic partnership incl investm in Sofinnova Partners + up to $1b capital |
2022-05-16 |
| HH2E–Foresight Group: investment, 202205 financing round totalling at least €12m incl Foresight Group acquiring minority share |
2022-05-16 |
| HH2E–HydrogenOne Capital: investment, 202205 financing round totalling at least €12m incl HydrogenOne Capital acquiring minority share |
2022-05-16 |
| HH2E–SEVERAL: investment, 202205 financing round at least €12m with HydrogenOne Capital + Foresight Group aquiring minoirty stakes ANNOUNCED |
2022-05-16 |
| Proteros–Trophic Communications: public relations, 202205 service existent by Trophic |
2022-05-16 |
| Sofinnova–Apollo Global Management: investment, 202205– acquisition of minority equity interest in Sofinnova Partners as part of strategic partnership |
2022-05-16 |
| Sofinnova–Apollo Global Management: investment, 202205– commitment of up to $1b managed capital to Sofinnova Partners investment funds by Apollo |
2022-05-16 |
| Enzymaster–SEVERAL: investment, 202205 financing round Series C over $45m (CYN300m) led by Yuanbio Venture Capital |
2022-05-12 |
| BLIRT–Qiagen: investment, 202205 acquisition 96% ownership stake by Qiagen |
2022-05-11 |
| Biohaven Pharmaceuticals–HBM: investment, 202205 investment existent worth $67m at time of announced $11.6b acquisition of Biohaven by Pfizer |
2022-05-10 |
| Biohaven Pharmaceuticals–Pfizer: investment, 202205– acquisition $11.6b in cash at $148.5/share excluding non-CGRP pipeline ANNOUNCED |
2022-05-10 |
| Domain Therapeutics–SEVERAL: investment, 202205 financing round Series A €39m co-led by Panacea Venture + CTI Life Sciences + 3B Future Health Fund |
2022-05-10 |
| Sidekick Health–SEVERAL: investment, 202205 financing round Series B $55m led by Novator Ventures |
2022-05-05 |
| Sidekick Health–Wellington Partners: investment, 202205 financing round Series B totalling $55m incl existing + co-investor Wellington Partners |
2022-05-05 |
| Engimmune Therapeutics–SEVERAL: investment, 202205 seed financing round CHF15.5m co-led by Pureos Bioventures + Novo Seeds |
2022-05-03 |
| Tubulis–Andera Partners: investment, 202205 financing round Series B totalling €60m incl new + lead investor Andera Partners |
2022-05-03 |
| Tubulis–Bavaria (govt): investment, 202205 financing round Series B totalling €60m incl existing + co-investor Wachstumsfonds Bayern 2 |
2022-05-03 |
| Tubulis–BioMedPartners: investment, 202205 financing round Series B totalling €60m incl existing + co-investor BioMedPartners |
2022-05-03 |
| Tubulis–BPCE: investment, 202205 financing round Series B totalling €60m incl existing + co-investor Seventure Partners |
2022-05-03 |
| Tubulis–Evotec: investment, 202205 financing round Series B totalling €60m incl new + co-investor Evotec |
2022-05-03 |
| Tubulis–Fund+: investment, 202205 financing round Series B totalling €60m incl new + co-investor Fund+ |
2022-05-03 |
| Tubulis–Germany (govt): investment, 202205 financing round Series B totalling €60m incl existing + co-investor Coparion |
2022-05-03 |
| Tubulis–High-Tech Gründerfonds: investment, 202205 financing round Series B totalling €60m incl existing + co-investor HTGF |
2022-05-03 |
| Tubulis–Occident: investment, 202205 financing round Series B totalling €60m incl existing + co-investor Occident |
2022-05-03 |
| Tubulis–SEVERAL: investment, 202205 financing round Series B €60m led by new investor Andera Partners |
2022-05-03 |
| Bionter–Dynamk Capital: investment, 202204 Series Seed financing $3m from Dynamk Capital |
2022-04-27 |
| Boehringer–CDR-Life: ophthalmic, 202204 collab development existent of antibody fragment-based therapeutic CDR202 for macular degeneration |
2022-04-13 |
| CDR-Life–Argot Partners: public relations, 202204 service existent media contact Argot Partners |
2022-04-13 |
| CDR-Life–Jeito Capital: investment, 202204 financing round Series A totalling $76m incl co-lead investor Jeito Capital |
2022-04-13 |
| CDR-Life–Omega Funds: investment, 202204 financing round Series A totalling $76m incl co-investor Omega Funds |
2022-04-13 |
| CDR-Life–RA Capital: investment, 202204 financing round Series A totalling $76m incl co-lead investor RA Capital Management |
2022-04-13 |
| CDR-Life–SEVERAL: investment, 202204 financing round Series A $76m co-led by Jeito Capital + RA Capital |
2022-04-13 |
| Cimeio Therapeutics–Versant Ventures: investment, 202204– Series A $50m commitment at launch from Versant Ventures |
2022-04-13 |
| Sierra Oncology–HBM: investment, 202204 existent investment of HBM at time of announced $1.9b acquisition of Sierra Oncology by GSK |
2022-04-13 |
| Affimed–SEVERAL: investment, 202204 public offering $90m+$13.5m with 22.5m+3.375m common shares at $4/share PRICED |
2022-04-12 |
| Avi Medical–Balderton Capital: investment, 202204 financing round Serise B totalling €50m incl lead investor Balderton Capital |
2022-04-06 |
| Avi Medical–SEVERAL: investment, 202204 financing round Series B €50m led by Balderton Capital |
2022-04-06 |
| IonSense–Bruker: investment, 202204 acquisition of IonSense by Bruker |
2022-04-06 |
| Regeneron–ViGeneron: gene therapy, 202204– collab + option agreem to develop vgAAV-based therapeutics for one inherited retinal disease target |
2022-04-06 |
| Merck (DE)–Lonza: MAST platform, 202204 acquisiton €na of MAST automated bioreactor sampling system by Merk Life Science from Lonza |
2022-04-05 |
| Optimal Industrial–Bruker: investment, 202204 acquisition €na of Optimal Industrial Automation + Technologies by Bruker |
2022-04-05 |
| Boehringer–Celeris Therapeutics: targeted protein degraders, 202204– collab AI-based drug discovery for target of Boehringer |
2022-04-04 |
| Labster–SEVERAL: investment, 202204 financing round Series C 2nd tranche $47m bringing total Series C to $107m |
2022-04-04 |
| Andes–Bayer: investment, 202204 existent portfolio company of Leaps by Bayer |
2022-04-01 |
| Biovox–SEVERAL: investment, 202204 pre-seed financing round with mid-6-figure € amount from business angels |
2022-04-01 |
| Ebenbuild–Bavaria (govt): investment, 202203 seed financing round totalling €2.5m incl co-lead investor Bayern Kapital |
2022-03-31 |
| Ebenbuild–High-Tech Gründerfonds: investment, 202203 seed financing round totalling €2.5m incl co-lead investor HTGF |
2022-03-31 |
| Ebenbuild–OTHER: investment, 202203 seed financing round totalling €2.5m incl well-known business angels as co-investors |
2022-03-31 |
| Ebenbuild–SEVERAL: investment, 202203 seed financing round €2.5m co-led by HTGF + Bayern Kapital with business angels |
2022-03-31 |
| Immunic–4SC: vidofludimus, 202103 settlement of remaining royalty obligations for IMU-838 for $17.25m with 50% in cash + 50% in Immunic common stock |
2022-03-31 |
| Asahi Kasei–VectivBio: apraglutide, 202203– excl license $30m upfront + $170m milestones + royalties for developm + marketing in Japan |
2022-03-30 |
| Neuron23–HBM: investment, 202203 financing round Series C totalling $100m incl existing + co-investor HBM Partners |
2022-03-30 |
| Neuron23–SEVERAL: investment, 202203 financing round Series C $100m led by SoftBank Vision Fund 2 |
2022-03-30 |
| VectivBio–Kreos Capital: credit, 202203– loan facility up to $75m with minimum draw down of $10m |
2022-03-30 |
| Core Biogenesis–Thia Ventures: investment, 202203 financing round Series A totalling €10m incl new + co-investor Thia Ventures |
2022-03-29 |
| Sanofi–IGM Biosciences: IgM antibody agonists, 202203– collab RnD + commerc ww excl $150m upfront + >$6b milestones for cancer + inflammation |
2022-03-29 |
| Innovacell–EU (govt): credit, 202203– venture debt loan of up to €15m from EIB to Innovacell AG |
2022-03-24 |
| Irubis–EU (govt): credit, 202203– convertible loan €500k from EIC Fund as part of EIC Accelerator Pilot programme |
2022-03-24 |
| Immatics–Trophic Communications: public relations, 202203 service existent by Trophic |
2022-03-23 |
| Aerium Therapeutics–F-Prime: investment, 202203 financing round Series A incl new + co-investor F-Prime Capital |
2022-03-22 |
| Aerium Therapeutics–Omega Funds: investment, 202203 financing round Series A incl existing seed + lead investor Omega Funds |
2022-03-22 |
| Aerium Therapeutics–SEVERAL: investment, 202203 emerges with substantial financing round Series A led by seed investor Omega Funds |
2022-03-22 |
| Affini-T Therapeutics–SEVERAL: investment, 202203 financing round $175m co-led by Vida Ventures + Leaps by Bayer |
2022-03-22 |
| ITM–ICIF: investment, 202203 financing round totalling €33m incl new investor Indigenous Critical Infrastructure Fund Canada |
2022-03-22 |
| ITM–Portland Holdings: investment, 202203 financing round totalling €33m incl exisiting investor PE fund managed by Portland Investment Counsel Inc |
2022-03-22 |
| ITM–SEVERAL: investment, 202203 financing round €33m from ICIF + PE fund managed by Portland Investment Counsel Inc |
2022-03-22 |
| Nucleai MD–Debiopharm: investment, 202203 financing round Series B totalling $33m incl existing + co-investor Debiopharm |
2022-03-22 |
| Nucleai MD–SEVERAL: investment, 202203 financing round Series B $33m co-led by Section 32 + Sanofi Ventures |
2022-03-22 |
| Nagi Bioscience–Switzerland (govt): grant, 202203 SERI-funded €2.5m EIC Accelerator program grant |
2022-03-21 |
| BigOmics–Eppendorf: investment, 202203 investment from Eppendorf Innovation Company (EpIC) closes pre-Series A round |
2022-03-17 |
| Gilde Investment–SEVERAL: investment, 202203 first + final close of €517m Gilde Healthcare Private Equity IV fund |
2022-03-16 |
| Precirix–SEVERAL: investment, 202203 financing round Series B €80 co-led by new investors Inkef Capital + Jeito Capital + Forbion |
2022-03-16 |
| BMS–Temedica: digital companion diagnostic, 202203– collab development digital companion diagnostic for psoriasis patients |
2022-03-15 |
| InfanDx–SEVERAL: investment, 202203 financing round Series A 2nd closing €2m from new + existing investors bringing total Series A to €6m |
2022-03-15 |
| PrognomiQ–Bruker: investment, 202203 financing round totalling $46m incl lead investor Bruker Corp |
2022-03-15 |
| PrognomiQ–SEVERAL: investment, 202203 financing round $46m led by Bruker Corp |
2022-03-15 |
| Ayoxxa–btov Partners: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor b-to-v Partners Sàrl |
2022-03-14 |
| Ayoxxa–Equivation: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Equivation-Beteiligungs-GmbH |
2022-03-14 |
| Ayoxxa–North Rhine-Westphalia (govt): investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor NRW.Bank |
2022-03-14 |
| Ayoxxa–PERSON: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Rainer Christine Asset Management GmbH |
2022-03-14 |
| Ayoxxa–PERSON: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Riesner Verwaltungs GmbH |
2022-03-14 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 7 8 9 ... 42 43 44 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
